Envestnet Asset Management Inc. Sells 20,851 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Envestnet Asset Management Inc. lowered its holdings in Exact Sciences Co. (NASDAQ:EXASGet Rating) by 6.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 322,596 shares of the medical research company’s stock after selling 20,851 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.18% of Exact Sciences worth $22,556,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. FSB Premier Wealth Management Inc. bought a new position in shares of Exact Sciences during the 4th quarter worth approximately $36,000. Masso Torrence Wealth Management Inc. bought a new position in shares of Exact Sciences during the 4th quarter worth approximately $37,000. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Exact Sciences during the 4th quarter worth approximately $37,000. HM Payson & Co. raised its stake in shares of Exact Sciences by 118.6% during the 4th quarter. HM Payson & Co. now owns 481 shares of the medical research company’s stock worth $37,000 after acquiring an additional 261 shares in the last quarter. Finally, Capital Advisory Group Advisory Services LLC bought a new position in shares of Exact Sciences during the 1st quarter worth approximately $37,000. Institutional investors own 94.45% of the company’s stock.

Exact Sciences Stock Performance

NASDAQ EXAS opened at $47.93 on Wednesday. The stock has a 50-day simple moving average of $44.74 and a two-hundred day simple moving average of $59.50. The firm has a market capitalization of $8.43 billion, a P/E ratio of -11.09 and a beta of 1.32. Exact Sciences Co. has a fifty-two week low of $35.34 and a fifty-two week high of $110.05. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.29 and a current ratio of 2.53.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, Director Katherine S. Zanotti sold 4,608 shares of Exact Sciences stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total transaction of $208,005.12. Following the completion of the transaction, the director now owns 60,318 shares in the company, valued at approximately $2,722,754.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Katherine S. Zanotti sold 1,086 shares of Exact Sciences stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $40.13, for a total value of $43,581.18. Following the completion of the transaction, the director now owns 60,318 shares in the company, valued at approximately $2,420,561.34. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Katherine S. Zanotti sold 4,608 shares of Exact Sciences stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $45.14, for a total value of $208,005.12. Following the completion of the transaction, the director now owns 60,318 shares of the company’s stock, valued at approximately $2,722,754.52. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,701 shares of company stock worth $251,872. Insiders own 1.40% of the company’s stock.

Analysts Set New Price Targets

EXAS has been the subject of several recent analyst reports. Piper Sandler initiated coverage on shares of Exact Sciences in a research note on Thursday, June 2nd. They set a “neutral” rating and a $50.00 price objective for the company. The Goldman Sachs Group decreased their price target on shares of Exact Sciences from $100.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, April 19th. Raymond James dropped their price objective on shares of Exact Sciences from $90.00 to $80.00 in a report on Wednesday, April 27th. Craig Hallum reduced their target price on Exact Sciences from $100.00 to $81.00 in a research note on Wednesday, April 27th. Finally, Cowen set a $83.00 target price on Exact Sciences in a research note on Tuesday, July 19th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $90.82.

About Exact Sciences

(Get Rating)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.

Featured Articles

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASGet Rating).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Want More Great Investing Ideas?

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.